Journal article
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
Blood, Vol.119(18), pp.4129-4132
05/03/2012
DOI: 10.1182/blood-2012-01-402792
PMCID: PMC3359734
PMID: 22343727
Abstract
In classical Hodgkin lymphoma, circulating clonotypic malignant cells express CD20, which potentially explains the observed activity of rituximab. This multicenter phase 2 study investigated the combination of rituximab-ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated classical Hodgkin lymphoma. A goal was to assess the behavior of circulating clonotypic B cells clinically. Of 49 evaluable patients, 69% had stage IIB-IV disease; 8% had CD20
+
Hodgkin and Reed-Sternberg cells. Rituximab-ABVD was generally well tolerated. Delivered relative dose intensity was 94% for AVD and 79% for bleomycin. After 6 cycles, 81% of patients were in complete remission. Only 8% received radiation therapy. The actuarial 3-year event-free and overall survival rates were 83% and 98%, respectively. EBV copy number in plasma fell dramatically during cycle 1 in patients with EBV
+
tumors. Persistence of detectable circulating clonotypic B cells was associated with a greater relapse frequency (
P
< .05). Rituximab-ABVD and clonotypic B cells warrant additional study in classical Hodgkin lymphoma. This trial was registered at
www.clinicaltrials.gov
as NCT00369681.
Details
- Title: Subtitle
- Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
- Creators
- Yvette L Kasamon - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MDHeather A Jacene - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MDChristopher D Gocke - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MDLode J Swinnen - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MDDouglas E Gladstone - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MDBrandy Perkins - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MDBrian K Link - University of Iowa, Iowa City, IALeslie L Popplewell - City of Hope Medical Center, Duarte, CA; andThomas M Habermann - Mayo Clinic, Rochester, MNJoseph M Herman - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MDWilliam H Matsui - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MDRichard J Jones - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MDRichard F Ambinder - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
- Resource Type
- Journal article
- Publication Details
- Blood, Vol.119(18), pp.4129-4132
- Publisher
- American Society of Hematology
- DOI
- 10.1182/blood-2012-01-402792
- PMID
- 22343727
- PMCID
- PMC3359734
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Grant note
- K23 CA124465; P01 CA015396 / National Institutes of Health
- Language
- English
- Date published
- 05/03/2012
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094528302771
Metrics
12 Record Views